Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer

Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer

IntroductionProgrammed death-ligand 1 (PD-L1) blockade is a growing treatment for extensive-stage small cell lung cancer (ES-SCLC). This study evaluates the cost-effectiveness of benmelstobart and anlotinib plus etoposide/carboplatin (EC) compared versus anlotinib plus EC and EC alone for patients w...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jing Nie, Conghui Kou, Ke Tang, Siyu Dai, Xifeng Zhao, Jiyong Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Pharmacology
Subjects:	extensive-stage small-cell lung cancer benmelstobart anlotinib carboplatin etoposide cost-effectiveness
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1524108/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer
by: Maojin You, et al.
Published: (2024-11-01)

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China
by: Caicong You, et al.
Published: (2024-12-01)

Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China
by: Chunyan Yan, et al.
Published: (2025-03-01)

Anlotinib combined with benmelstobart as a chemo-free first-line treatment in advanced esophageal squamous cell carcinoma: an exploratory multicenter, single-arm phase II clinical trial
by: Xiangrui Meng, et al.
Published: (2025-06-01)

A Case of Small Cell Carcinoma of Bladder With Significant Tumor Reduction Following Combination Chemotherapy and Radiation Therapy
by: Rintaro Yoshitake, et al.
Published: (2025-05-01)

Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer
by: Michitoshi Yabe, et al.
Published: (2025-06-01)

Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study
by: Chen TF, et al.
Published: (2025-06-01)

Efficacy of PD-(L)1 inhibitors plus anlotinib in the second-line treatment of extensive-stage small cell lung cancer
by: Jian Zhang, et al.
Published: (2025-07-01)

Vaginal Bleeding in an Infant due to Extragonadal Germ Cell Tumor: A Case Report with Review of Literature
by: Ayesha Amanath Assadi, et al.
Published: (2024-11-01)

Risk Factors for Prognosis of Lung Cancer Patients Receiving Anlotinib Treatment: A Retrospective Cohort Study
by: Congyi Xie, et al.
Published: (2025-02-01)

Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma
by: Mingfang Xu, et al.
Published: (2025-07-01)

Anlotinib-associated pulmonary embolism in brainstem glioblastoma treatment: a case report
by: Jia-Lan Zhao, et al.
Published: (2025-04-01)

Tumor Cavitation with Anlotinib Treatment in Lung Adenocarcinoma
by: Jie Huang, et al.
Published: (2025-05-01)

Hypersensitivity reaction to etoposide. A case report
by: M. Mullera Martí, et al.
Published: (2014-05-01)

Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Longfeng Zhang, et al.
Published: (2025-07-01)

RAF1 promotes anlotinib resistance in non-small cell lung cancer by inhibiting apoptosis
by: Shuo Wu, et al.
Published: (2025-04-01)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
by: Ming Ouyang, et al.
Published: (2025-08-01)

Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer
by: Bin Liu, et al.
Published: (2025-06-01)

Radiotherapy combined with anlotinib for refractory leiomyosarcoma: a case report and literature review
by: Ziming Li, et al.
Published: (2025-07-01)

Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study
by: Zhiyong Li, et al.
Published: (2025-12-01)

Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy
by: Jianquan Yang, et al.
Published: (2025-07-01)

Iodine-125 seeds combined with anlotinib in the treatment of recurrent retroperitoneal liposarcoma after surgery: a case report
by: Gaoyan Tang, et al.
Published: (2025-04-01)

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation
by: Yilamujiang Ainiwan, et al.
Published: (2025-03-01)

Cytotoxic Effect of Escitalopram/Etoposide Combination on Etoposide-Resistant Lung Cancer
by: Serap Özkaya Gül, et al.
Published: (2025-04-01)

Rapid Response to Penpulimab Combined With Anlotinib and Chemotherapy in a Thoracic SMARCA4‐UT Without PD‐L1 Expression: A Case Report and Review of Literature
by: Yuanhang Wang, et al.
Published: (2024-12-01)

Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study
by: Xiaoli Liu, et al.
Published: (2025-03-01)

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
by: Ying Cheng, et al.
Published: (2020-04-01)

Anlotinib combined with penpulimab in the treatment of advanced adult thoracic spinal osteosarcoma: a case report
by: Xiaochun Chen, et al.
Published: (2025-07-01)

Anlotinib induced type 1 diabetes: a case report
by: Jing Chen, et al.
Published: (2025-04-01)

Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study
by: Yu Hua, et al.
Published: (2025-05-01)

Efficacy of toripalimab in combination with anlotinib in recurrent undifferentiated pleomorphic sarcoma of the sinonasal region: a case report with biomarker analysis
by: Fang Wu, et al.
Published: (2025-05-01)

The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
by: Xiaobing Li, et al.
Published: (2024-12-01)

Synergistic effects of anlotinib and DDP on breast cancer: targeting the VEGF/JAK2/STAT3 axis
by: Hongmei Zhang, et al.
Published: (2024-10-01)

Efficacy and safety of Cadonilimab plus anlotinib in small cell lung cancer with brain metastases
by: Hai-Zhen Yi, et al.
Published: (2025-07-01)

Feasibility and Safety of Anlotinib Plus Docetaxel versus Docetaxel Monotherapy in Patients with Previously Immunotherapy-Treated NSCLC: A Retrospective Exploratory Study
by: Li DW, et al.
Published: (2025-04-01)

Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trialResearch in context
by: Suying Lu, et al.
Published: (2025-06-01)

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib
by: Yingfang Feng, et al.
Published: (2025-07-01)

Efficacy and safety of anlotinib monotherapy or combination therapy in the treatment of patients with advanced non-small cell lung cancer: a retrospective real-world study conducted in East China
by: Jia Wei, et al.
Published: (2025-04-01)

N6‐Methyladenosine modification mediated by METTL3 promotes DNA‐PKcs expression to induce anlotinib resistance in osteosarcoma
by: Yining Zhang, et al.
Published: (2025-02-01)

Cost-effectiveness analysis of Toripalimab regimen for extensive-stage small-cell lung cancer in China and America
by: Jing Yang, et al.
Published: (2025-05-01)